Agreements

Date: 2014-11-06

Type of information: Nomination

Compound: vice-president, chief commercial officer

Company: Paratek Pharmaceuticals (USA - MA)

Therapeutic area: Infectious diseases

Type agreement: nomination

Action mechanism:

Disease:

Details:

• • On November 4 and 6, 2014, Paratek Pharmaceuticals announced the addition of several experienced individuals to its management team and presented its newly expanded board of directors. The newly expanded team will focus primarily on the development and commercialization of Paratek's broad-spectrum IV and oral once daily antibiotic candidate, omadacycline, intended for serious community-acquired bacterial infections where resistance is of concern to prescribing physicians.
• Adam Woodrow joins Paratek as Chief Commercial Officer. Mr. Woodrow has over 20 years of experience in leading the commercialization of brands across small molecules and proteins from pre-clinical to commercial launch. Prior to joining Paratek, he led commercial development in Pfizer\'s Specialty Care Business Unit, launching products for rheumatoid arthritis and rare disease. In addition, he led global strategic marketing for a range of products from rare disease to acute hospital based infections, including Enbrel®, Zyvox®, ReFacto® and Benefix®. Mr. Woodrow joined Pfizer from Wyeth Pharmaceuticals, where he was Vice President and Global Business Manager for Enbrel and inflammation. In his 10 years at Wyeth Pharmaceuticals, he held senior marketing and sales positions in the United States and in Europe. He was responsible for the successful launches of medicines in the fields of anti-infectives (Tygacil®) and hemophilia (ReFacto®).
• Evan Tzanis joined Paratek in September 2014 as Vice President of Clinical Development. He will oversee the clinical development program for omadacycline, including the design and operational oversight of clinical trials, biometrics and regulatory affairs. Mr. Tzanis brings over 20 years of global drug development experience in all aspects of clinical strategy, clinical operations and regulatory processes. Prior to joining Paratek, Mr. Tzanis served as Head of Clinical Operations and Biometrics at Endo Pharmaceuticals where he also had leadership responsibility in clinical and project management. During his tenure with Endo Pharmaceuticals, Mr. Tzanis was responsible for several late stage development programs, including BEMA® Buprenorphine, which successfully completed Phase 3 clinical development. Prior to joining Endo Pharmaceuticals, Mr. Tzanis was the Global Clinical Program Leader at Wyeth Pharmaceuticals and Pfizer for a number of successfully approved new products that remain on the global market today to treat a range of central nervous system disorders including panic disorder, major depressive disorder, sleep and other medical conditions, including, opioid induced constipation and rheumatoid arthritis.
• Sue M. Perkins is also joining Paratek as Vice President, Intellectual Property. Ms. Perkins is an attorney who brings substantial experience in the protection and enhancement of pharmaceutical-related intellectual property assets to Paratek. She has worked in a law firm preparing and prosecuting both domestic and foreign patent applications. Ms. Perkins has also been in-house counsel for five different pharmaceutical companies, including Aileron Therapeutics, Avila Therapeutics and Syntonics Pharmaceuticals. Her experience spans both small molecule and bio-therapeutics and she is a former patent examiner at the US Patent and Trademark office.
• The members of the newly expanded board of directors are Michael F Bigham, Thomas J. Dietz, Ph.D, Robert Radie, Jeffrey Stein, Ph.D., Richard Lim, and Evan Loh M.D.
• Michael F. Bigham, appointed Chief Executive Officer and Chairman of the board of directors of Paratek in June 2014. Mr. Bigham has more than 25 years of senior leadership experience in the biopharmaceutical industry. Since 2003, he has been a Partner at Abingworth LLP, a leading international investment group dedicated to life sciences and healthcare. He currently serves on the boards of Avedro and Secure EDI, where he is Chairman, and has held several directorships, including at Avila Therapeutics (where he was also the founding Chairman and CEO), Magellan Biosciences, Portola Pharmaceuticals, Supernus Pharmaceuticals and Valeritas. Mr. Bigham was formerly Vice Chairman of Corixa Corporation, a publicly traded biotechnology company, and was President and Chief Executive of Coulter Pharmaceuticals, a publicly-traded oncology company, until it merged into Corixa. Previously, he was an early employee at Gilead Sciences where he served in various capacities, including Executive Vice President of Operations and Chief Financial Officer. Before joining Gilead, Mr. Bigham was a Partner at Hambrecht & Quist where he became Co-Head of Healthcare Investment Banking. Mr. Bigham received his B.S. from the University of Virginia and qualified as a C.P.A. before completing his M.B.A. at Stanford University.
• Thomas J. Dietz, Ph.D., was a member of Transcept\'s board of directors since his appointment in April 2013. Dr. Dietz has served as Chairman and CEO of Waypoint Holdings, LLC, a financial services firm, since December 2010. He was previously co-CEO and then CEO and a director of Pacific Growth Equities, LLC, an investment bank and institutional brokerage firm, from 2004 to January 2009, when Wedbush Securities acquired the firm. Dr. Dietz subsequently served as head of the investment banking division at Wedbush until November 2010. He joined Pacific Growth in 1993 and served in various roles, including senior roles in equities research and investment banking, prior to assuming the CEO role. Previously, Dr. Dietz was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center. Dr. Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University in St. Louis.
• Robert Radie, has been President and Chief Executive Officer of Egalet since March 2012. From November 2010 to October 2011, Mr. Radie served as President and Chief Executive Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in 2011. From March 2009 to November 2010, he served as President and Chief Executive Officer of Transmolecular, Inc., a biotechnology company developing cancer diagnostic and treatment products, after serving as a consultant to Transmolecular from December 2008 through March 2009. From September 2007 to September 2008, Mr. Radie served as the Chief Business Officer of Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company. Before joining Prestwick, Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and Eli Lilly and Company. Mr. Radie has served as a director of Horse Power For Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer, since 2007. Mr. Radie received his B.S. in chemistry from Boston College.
• Jeffrey Stein, Ph.D., has been President and Chief Executive Officer of Cidara Therapeutics since 2014. Prior to joining Cidara, Dr. Stein was Chief Executive Officer of Trius Therapeutics from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September of 2013. Dr. Stein is also founding Chairman and President of the Antibiotics Working Group, an industry lead 501(c)(6) organization. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm\'s San Diego office in 2005. Prior to joining Sofinnova, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at UCSD.
• Richard Lim has been a member of Paratek\'s board of directors since March 2014. Mr. Lim is a General Partner at Omega Funds and has over 20 years in principal investment and strategic consulting, all within life science and healthcare. He was previously a General Partner at MVM Life Science Partners, a life science focused venture capital firm with $500 million under management; he founded MVM\'s US investment operations. He was previously a Vice President at Saunders, Karp & Megrue (SKM), a private equity firm with $1.7 billion under management, where he specialized in healthcare growth capital and leveraged transactions. Prior to SKM (now known as Apax Partners Inc.), Mr. Lim was a Manager at LEK Consulting, providing strategic advice to life science companies; he consulted for more than 3 dozen small and large biotechnology firms. He was also an Associate with M&A investment bank BT Wolfensohn. He has served on a number of boards in biotechnology, specialty pharmaceuticals, and medical device companies. He serves as a catalyst advisor of the Deshpande Center at the Massachusetts Institute of Technology. He earned his A.B. from Harvard University and his M.B.A. from Harvard Business School.

Financial terms:

Latest news:

Is general: Yes